Evidence map›Paper›PMID 37091238›Full record

ArticleiScience2023

Implementing best practices on data generation and reporting of

Rob C van Wijk, Ainhoa Lucía, Pavan Kumar Sudhakar, Lindsay Sonnenkalb, Cyril Gaudin, Eik Hoffmann, Bérénice Dremierre, Diana Angélica Aguilar-Ayala, Michael Dal Molin, Jan Rybniker and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Antimicrobial agents and chemotherapy · 2026
    Article
  2. Frontiers in microbiology · 2026
    Article
  3. Article
  4. Structure of the SigE regulatory network inFrontiers in microbiology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Rob C van WijkDepartment of Pharmaceutical Biosciences, Uppsala University, 75124 Uppsala, Sweden.
Ainhoa LucíaDepartment of Microbiology, Faculty of Medicine, University of Zaragoza, 50009 Zaragoza, Spain.
Pavan Kumar SudhakarData collaboration center, Critical Path Institute Ltd, D11 YNR2 Dublin, Ireland.
Lindsay SonnenkalbMolecular and Experimental Mycobacteriology, Research Center Borstel Leibniz Lung Center, 23845 Borstel, Germany.
Cyril GaudinCenter for Infection and Immunity of Lille, Institut Pasteur de Lille, 59019 Lille, France.
Eik HoffmannCenter for Infection and Immunity of Lille, Institut Pasteur de Lille, 59019 Lille, France.
Bérénice DremierreCenter for Infection and Immunity of Lille, Institut Pasteur de Lille, 59019 Lille, France.
Diana Angélica Aguilar-AyalaDepartment of Microbiology, Faculty of Medicine, University of Zaragoza, 50009 Zaragoza, Spain.
Michael Dal MolinDepartment I of Internal Medicine, Division of Infectious Diseases, University of Cologne, 50937 Cologne, Germany.
Jan RybnikerDepartment I of Internal Medicine, Division of Infectious Diseases, University of Cologne, 50937 Cologne, Germany.
Stefano de GiorgiDepartment of Molecular Medicine, University of Padova, 35121 Padova, Italy.
Laura Cioetto-MazzabòDepartment of Molecular Medicine, University of Padova, 35121 Padova, Italy.
Greta SegafreddoDepartment of Molecular Medicine, University of Padova, 35121 Padova, Italy.
Riccardo ManganelliDepartment of Molecular Medicine, University of Padova, 35121 Padova, Italy.
Giulia DegiacomiDepartment of Biology and Biotechnology Lazzaro Spallanzani, University of Pavia, 27100 Pavia, Italy.
Deborah RecchiaDepartment of Biology and Biotechnology Lazzaro Spallanzani, University of Pavia, 27100 Pavia, Italy.
Maria Rosalia PascaDepartment of Biology and Biotechnology Lazzaro Spallanzani, University of Pavia, 27100 Pavia, Italy.
Ulrika S H SimonssonDepartment of Pharmaceutical Biosciences, Uppsala University, 75124 Uppsala, Sweden.
Santiago Ramón-GarcíaDepartment of Microbiology, Faculty of Medicine, University of Zaragoza, 50009 Zaragoza, Spain.
ERA4TB consortium

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tuberculosis (TB) is the historical leading cause of death by a single infectious agent. The European Regimen Accelerator for Tuberculosis (ERA4TB) is a public-private partnership of 30+ institutions with the objective to progress new anti-TB regimens into the clinic. Thus, robust and replicable results across independent laboratories are essential for reliable interpretation of treatment efficacy. A standardization workgroup unified

Indexed as

Biochemical assayMolecular modellingTreatment

Identifiers

PMID37091238
PMCPMC10119593

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.